Poster Abstract Session:
231. Clinical Study with New Antibiotics and Antifungals
Saturday, October 7, 2017: 12:30 PM-2:00 PM
Room: Poster Hall CD


Presentations:
Meropenem-Vaborbactam Pharmacokinetics in Subjects with Chronic Renal Impairment, Including Hemodialysis
Christopher M. Rubino, PharmD ; David C. Griffith, B.A. ; Sujata M. Bhavnani, Pharm.D., M.S. ; Jeffrey S. Loutit, MBChB ; Brooke Lohse, BA ; Michael N. Dudley, Pharm.D., FIDSA ; Paul G. Ambrose, Pharm.D., FIDSA
First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
Michael R. Hodges, MBBS, BSc ; Eric Ople, BSc ; Karen J. Shaw, PhD ; Robert Mansbach, PhD ; Sjoerd J. Van Marle, MD ; Ewoud-Jan Van Hoogdalem, PharmD PhD ; Pamela Wedel, BSc ; William Kramer, PhD
Posters
  • 1840_IDWPOSTER - upload.pdf (313.7 kB)
  • A Phase 1 Study in Healthy Subjects to Investigate Safety, Pharmacokinetics, and Effect on Intestinal Flora of Multiple Ascending Doses of DS-2969b, A Novel Oral DNA Gyrase B Inhibitor for The Treatment of Clostridium difficile Infection
    Satoshi Inoue, MD, Ph.D ; Justin Dennie, PharmD ; Yasuo Nagasawa, Ph.D ; Roohi Gajee, Ph.D ; Nobuhisa Masuda, PhD ; Cynthia Zamora, MD ; Giorgio Senaldi, MD, Ph.D
    Posters
  • POSTER231_1841.pdf (235.8 kB)
  • Preservation of gut microbiome following ridinilazole versus fidaxomicin treatment of Clostridium difficile infection
    Suparna Mitra, PhD ; Caroline Chilton, PhD ; Jane Freeman, PhD ; Henry Wood, PhD ; Phil Quirke, BM, PhD ; Morag Taylor, M.Sc ; Richard Vickers, PhD ; Mark Wilcox, MD
    SYN-004 (ribaxamase) Protects the Diversity of the Gut Microbiome in Patients Receiving Intravenous Ceftriaxone Treatment
    John Kokai-Kun, PhD ; Sheila Connelly, PhD ; Charles Le, PhD ; Kenneth Trout, MS ; Joseph Sliman, MD, PhD
    Posters
  • 2017-ID Week-Poster.pdf (829.6 kB)
  • Prevention of Lung Pathology and Mortality in Rabbit Staphylococcus aureus Pneumonia with Cytotoxin-Neutralizing Monoclonal IgGs that Penetrate Epithelial Lining Fluid
    Lukas Stulik, MSc ; Harald Rouha, PhD ; Delphine Labrousse, PhD ; Zehra Visram, PhD ; Gabor Nagy, MD, PhD ; Delphine Croisier, PhD ; Eszter Nagy, MD, PhD
    Intravenous Fosfomycin (ZTI-01) for the Treatment of Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP): Results from a Multi-center, Randomized, Double-Blind Phase 2/3 Study in Hospitalized Adults (ZEUS)
    Keith S. Kaye, MD, MPH ; Louis B. Rice, MD, FIDSA ; Aaron Dane, PhD ; Viktor Stus, MD, PhD ; Olexsiy Sagan, MD ; Elena Fedosiuk, MD ; Anita Das, PhD ; David Skarinsky, BS ; Paul B Eckburg, MD ; Evelyn J Ellis-Grosse, PhD
    Posters
  • Zavante_Poster1845_revCC KS.pdf (105.4 kB)
  • Ceftolozane/Tazobactam Dose Evaluation for Pediatric Subjects with Complicated Intra-Abdominal Infection and Complicated Urinary Tract Infection
    Kajal Larson, PhD ; Matthew G. Johnson, MPH ; Matthew L. Rizk, PhD ; Luzelena Caro, PhD ; John S. Bradley, MD, FIDSA, FPIDS, FAAP ; Jocelyn Ang, MD ; Elizabeth Rhee, MD
    Phase I Study To Evaluate The Pharmacokinetics Of Two Dosing Regimens Of Oral Fosfomycin Tromethamine In Healthy Adult Participants
    Eric Wenzler, PharmD ; Susan C. Bleasdale, MD ; Monica K. Sikka, MD ; Kristen Bunnell, PharmD ; Matthew Finnemeyer, MPH ; Susan L Rosenkranz, PhD ; Larry H. Danziger, Pharm.D., FIDSA ; Keith A. Rodvold, Pharm.D., FIDSA
    Population Pharmacokinetic (PPK) Analysis of ZTI-01 (Fosfomycin for Injection) Using Data from Healthy Subjects and Patients with Complicated Urinary Tract Infections (cUTI)
    Michael Trang, Pharm.D. ; Evelyn J. Ellis-Grosse, Ph.D. ; Paul B. Eckburg, M.D. ; David Skarinsky, B.S. ; Sujata M. Bhavnani, Pharm.D., M.S. ; Christopher M. Rubino, Pharm.D.
    Population Pharmacokinetic Model for Intravenous ASN100 in Healthy Subjects
    Scott A. Van Wart, Ph.D. ; Christopher Stevens, M.D. ; Zoltan Magyarics, M.D., Ph.D. ; Steven A. Luperchio, Ph.D. ; Paul G. Ambrose, Pharm.D., FIDSA
    A Pharmacometric Comparison of Omadacycline and Tigecycline Epithelial Lining Fluid (ELF) Penetration
    Elizabeth A. Lakota, Pharm.D., M.S. ; Keith A. Rodvold, Pharm.D., FIDSA ; Sujata M. Bhavnani, Pharm.D., M.S. ; Judith N. Steenbergen, Ph.D. ; Evan Tzanis, B.A. ; Paul G. Ambrose, Pharm.D., FIDSA ; Christopher M. Rubino, Pharm.D.
    Population Pharmacokinetic (PPK) and Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Support Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    Sujata M. Bhavnani, Pharm.D., M.S. ; Li Zhang, M.D., Ph.D. ; Paul G. Ambrose, Pharm.D., FIDSA ; Robert K. Flamm, Ph.D. ; Sue K. Cammarata, MD ; Christopher M. Rubino, Pharm.D.
    Meropenem-Vaborbactam Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses as Support for Dose Selection in Patients with Normal Renal Function and Varying Degrees of Renal Impairment
    Sujata M. Bhavnani, Pharm.D., M.S. ; Michael Trang, Pharm.D. ; David C. Griffith, B.A. ; Olga Lomovskaya, Ph.D. ; Jeffrey P. Hammel, M.S., B.S. ; Jeffrey S. Loutit, MBChB ; Michael N. Dudley, Pharm.D., FIDSA ; Paul G. Ambrose, Pharm.D., FIDSA ; Christopher M. Rubino, Pharm.D.
    Improved Outcomes with Plazomicin (PLZ) Compared with Colistin (CST) in Patients with Bloodstream Infections (BSI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE): Results from the CARE Study
    James A. McKinnell, MD ; Lynn E. Connolly, MD, PhD ; Richard Pushkin, MD ; Adrian M. Jubb, MBChB, PhD ; Bridget O'Keeffe, PhD ; Alisa W. Serio, PhD ; Alex Smith, MS ; Jonathan Gall, PharmD ; Valerie Riddle, MD ; Kevin M. Krause, MBA ; Jason M. Pogue, PharmD
    Posters
  • IDWeek 2017 Poster 1853.pdf (208.5 kB)
  • Plazomicin Versus Meropenem for Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP): Diagnosis-specific Results From the Phase 3 EPIC Study
    Daniel J. Cloutier, PharmD ; Allison S. Komirenko, PharmD ; Deborah S. Cebrik, MS, MPH ; Tiffany R. Keepers, PhD ; Kevin M. Krause, MBA ; Lynn E. Connolly, MD, PhD ; Florian M.E. Wagenlehner, MD
    Posters
  • IDWeek 2017 Poster 1855.PDF (132.8 kB)
  • Improved Outcomes at Late Follow-up (LFU) with Plazomicin Compared with Meropenem in Patients with Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) in the EPIC Study
    Yoav Golan, MD ; Daniel J. Cloutier, PharmD ; Allison S. Komirenko, PharmD ; Deborah S. Cebrik, MS, MPH ; Tiffany R. Keepers, PhD ; Kevin M. Krause, MBA ; Lynn E. Connolly, MD, PhD ; Florian M.E. Wagenlehner, MD
    Posters
  • IDWeek 2017 Poster 1859.PDF (175.1 kB)
  • Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability
    Michael R. Hodges, MBBS, BSc ; Eric Ople, BSc ; Karen J. Shaw, PhD ; Robert Mansbach, PhD ; Sjoerd P. Van Marle, MD ; Ewoud-Jan Van Hoogdalem, PharmD PhD ; William Kramer, PhD ; Pamela Wedel, BSc
    Posters
  • 1860 IDWPOSTER - upload.pdf (286.4 kB)
  • Clinical Outcomes of Serious Infections due to Carbapenem-Resistant Enterobacteriaceae (CRE) in TANGO II, a Phase 3, Randomized, Multi-National, Open-Label Trial of Meropenem-Vaborbactam (M-V) Versus Best Available Therapy (BAT)
    Keith S. Kaye, MD, MPH ; Jose Vazquez, MD, FACP, FIDSA ; Amy Mathers, MD ; George Daikos, MD ; Elizabeth Alexander, MD, MSc ; Jeffrey S. Loutit, MBChB ; Shu Zhang, PhD ; Michael N. Dudley, Pharm.D., FIDSA ; Oliver Cornely, MD, FACP, FIDSA, FAAM
    RBX2660 is Safe, Superior to Antibiotic-Treated Controls for Preventing Recurrent Clostridium difficile, and May Rehabilitate Patient Microbiomes: Open Label Trial Results
    Robert Orenstein, DO, FIDSA ; Erik R. Dubberke, MD, MSPH ; Sahil Khanna, MBBS, MS ; Gail Hecht, MD ; Herbert Dupont, MD ; Christine Lee, MD, FRCPC ; Ken Blount, PhD ; Sharina Carter, PhD
    Phase 3, randomized, double-blind noninferiority (NI) study of ceftazidime-avibactam (CAZ-AVI) versus meropenem (MER) in the treatment of patients with Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP): Analyses of the REPROVE study per US FDA Endpoints
    Antoni Torres, MD, PhD, FERS ; Doug Rank, MD ; Ludmyla Rekeda, PhD ; Xiang Chen, MS ; Todd Riccobene, PhD ; Ian Critchley, PhD ; Hassan Lakkis, PhD ; David Melnick, MD ; Joseph W. Chow, MD ; Dianna Taylor, BSc, PgC ; Peter J. Laud, MSc ; Angela K. Talley, MD
    Meropenem-Vaborbactam vs. Piperacillin-Tazobactam in TANGO I (a Phase 3 Randomized, Double-blind Trial): Outcomes by Baseline MIC in Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis
    Thomas J. Walsh, MD ; Tanaya Bhowmick, MD ; Rabih Darouiche, MD ; Valerii Zaitsev, MD, PhD ; Evangelos Giamarellos-Bourboulis, MD, PhD ; Andrew F. Shorr, MD, MPH ; Elena Fedosiuk, MD ; Thomas M. File Jr., MD, MSc, MACP, FIDSA, FCCP ; Jeffrey S. Loutit, MBChB ; Olga Lomovskaya, Ph.D. ; Michael N. Dudley, Pharm.D., FIDSA ; David Perlin, Ph.D.
    Meropenem-Vaborbactam vs. Best AvailableTherapy for Carbapenem-ResistantEnterobacteriaceae Infections in TANGO II: PrimaryOutcomes by Site of Infection
    Richard Wunderink, MD ; Evangelos Giamarellos-Bourboulis, MD ; Galia Rahav, MD ; Amy Mathers, MD ; Matteo Bassetti, MD, PhD ; Joseph Solomkin, MD, FIDSA ; Elizabeth Alexander, MD, MSc ; Jeffrey S. Loutit, MBChB ; Shu Zhang, PhD ; Michael N. Dudley, Pharm.D., FIDSA ; Keith S. Kaye, MD, MPH
    Meropenem-Vaborbactam vs. Best Available Therapy for Carbapenem-Resistant Enterobacteriaceae Infections in TANGO II: Outcomes in Immunocompromised Patients
    David L. Paterson, MB BS PhD FRACP FRCPA ; Eun J. Kwak, MD ; Tanaya Bhowmick, MD ; Elizabeth Alexander, MD, MSc ; Jeffrey S. Loutit, MBChB ; Shu Zhang, PhD ; Michael N. Dudley, Pharm.D., FIDSA ; Thomas J. Walsh, MD
    Clinical Response of Cefiderocol Compared with Imipenem/Cilastatin in the Treatment of Adults with Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis: Results from a Multicenter, Double-blind, Randomized Study (APEKS-cUTI)
    Simon Portsmouth, MD ; David Van Veenhuyzen, MBChB, MPharmMed ; Roger Echols, MD, FIDSA ; Mitsuaki Machida, MS ; Juan Camilo Arjona Ferreira, MD ; Mari Ariyasu, BA ; Tsutae Den Nagata, MD, PhD, FFPM
    Microbiome Profile is Distinct in Patients with Successful Response to Microbiota-Based Drug RBX2660 Relative to Placebo Responders
    Erik R. Dubberke, MD, MSPH ; Robert Orenstein, DO, FIDSA ; Christine Lee, MD, FRCPC ; Sahil Khanna, MBBS, MS ; Gail Hecht, MD ; Dale N Gerding, MD, FIDSA ; Ken Blount, PhD ; Bill Shannon, PhD, MBA
    Micafungin versus Posaconazole Prophylaxis in Patients with Acute Leukemia or Myelodysplastic Syndrome: A Randomized, Open-label Study
    David J. Epstein, MD ; Susan Seo, MD ; Yao-Ting Huang, PhD, MPH ; Jae Park, MD ; Virginia Kimek, MD ; Martin S. Tallman, MD ; Mark G. Frattini, MD, PhD ; Genovefa Papanicolaou, MD
    Posters
  • poster 1871.pdf (205.8 kB)
  • Immunogenicity of a 2+1 Infant Vaccination Series with 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV): a Randomized Trial Exploring Interchangeability of PCVs
    Abiel Mascareñas De Los Santos, MD ; Miguel Angel Rodríguez-Weber, MD ; Pedro Sánchez-Márquez, MD ; Roberto Carreño-Manjarrez, MD ; María Yolanda Cervantes-Apolinar, MD ; Javier Ruiz-Guiñazú, MD ; Eduardo Ortega-Barria, MD ; Dorota Borys, MD
    Assessment of MIC Increases with Meropenem-Vaborbactam and Ceftazidime-Avibactam in TANGO II (a Phase 3 Study of the Treatment of CRE Infections)
    Olga Lomovskaya, Ph.D. ; Mariana Castanheira, PhD ; Jose Vazquez, MD, FACP, FIDSA ; Keith S. Kaye, MD, MPH ; Kirk Nelson, BS ; Dongxu Sun, PhD ; Elizabeth Alexander, MD, MSc ; Michael N. Dudley, Pharm.D., FIDSA ; Michael Yin, MD
    Analysis of the Microbiological data from the Omadacycline (OMC) Phase 3 Community-Acquired Bacterial Pneumoniae (CABP) trial: The OPTIC study
    Eliana Armstrong, PhD ; Evan Tzanis, B.A. ; Amy Manley, BS ; Paul McGovern, MD ; Anita Das, PhD ; Judith N. Steenbergen, Ph.D.
    Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) with Dalbavancin in Patients with Systemic Inflammatory Response Syndrome (SIRS)
    Michael Nowak, PharmD ; Jennifer Nelson, PharmD ; Urania Rappo, MD ; Jie Chen, PhD ; Jamie Danelo, PharmD ; Pedro L. Gonzalez, MD ; Frank LoVecchio, DO, MPH
    Analysis of CAMERA-1 S. aureus Bacteremia Trial Results using the DOOR
    Thomas L. Holland, MD ; Joshua S. Davis, MBBS FRACP ; Sarah B. Doernberg, MD ; Thuy Tien T. Tran, MS ; Scott R. Evans, PhD ; Sara E. Cosgrove, MD, MS ; Helen W. Boucher, MD, FIDSA ; G. Ralph Corey, MD ; Vance Fowler Jr., MD, MHS ; Henry F. Chambers, MD ; Steven Y. C. Tong, MBBS, FRACP
    Meropenem-Vaborbactam: Outcomes in Subjects with Renal Impairment in Phase 3 Studies TANGO I and II
    Amy Mathers, MD ; William Hope, BMBS, FRACP, FRCPA, PhD ; Keith S. Kaye, MD, MPH ; Jeffrey S. Loutit, MBChB ; Elizabeth Alexander, MD, MSc ; Michael N. Dudley, Pharm.D., FIDSA ; Jose Vazquez, MD, FACP, FIDSA
    Phase I Study To Evaluate The Safety And Tolerability Of Two Dosing Regimens Of Oral Fosfomycin Tromethamine In Healthy Adult Participants
    Susan C. Bleasdale, MD ; Eric Wenzler, PharmD ; Monica K. Sikka, MD ; Kristen Bunnell, PharmD ; Matthew Finnemeyer, MPH ; Susan L Rosenkranz, PhD ; Larry H. Danziger, Pharm.D., FIDSA ; Keith A. Rodvold, Pharm.D., FIDSA
    Fosfomycin trometamol is noninferior to trimethoprim-sulfamethoxazole for acute uncomplicated cystitis in women
    Ann Stapleton, MD, FIDSA ; Pacita Roberts, MS ; Marsha Cox, MS ; Thomas Hooton, MD, FIDSA
    Pharmacokinetics (PK)/Pharmacodynamics (PD) and Safety of 3 g Ceftolozane/Tazobactam (TOL/TAZ) in Ventilated, Critically-Ill Patients
    Luzelena Caro, PhD ; Kajal Larson, PhD ; David P. Nicolau, PharmD, FCCP, FIDSA ; Jan De Waele, MD PhD ; Joseph L. Kuti, PharmD ; Elaine Gadzicki, BS ; Adedayo Adedoyin, PhD ; Zhen Zeng, Ph.D. ; Bernardino Mosquera, MD, MPH ; Ramanatha Saralaya, MPharm ; Elizabeth Rhee, MD
    A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of IV to Oral Omadacycline to Moxifloxacin for the Treatment of Adult Subjects with CABP (The OPTIC Study).
    Roman Stets, MD, PhD ; Monica Popescu, MD ; Joven Gonong, MD, FPCCP ; Ismail Mitha, MD ; William Nseir, MD ; Andrzej Madej, MD, PhD ; Courtney Kirsch, BS ; Anita Das, PhD ; Lynne Garrity-Ryan, PhD ; Judith N. Steenbergen, Ph.D. ; Amy Manley, BS ; Paul Eckburg, MD ; Stephen Villano, MD ; Evan Tzanis, B.A. ; Paul McGovern, MD ; Evan Loh, MD
    Ceftaroline Fosamil (CPT) versus Vancomycin (VAN) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    Trang D. Trinh, Pharm.D. ; Evan J. Zasowski, PharmD, BCPS ; Kimberly Claeys, PharmD, BCPS ; Abdalhamid M. Lagnf, M.P.H. ; Dino Delaportas, MD ; Sandy Estrada, Pharm.D., BCPS (AQ-ID) ; Susan L Davis, PharmD ; Kenneth Klinker, PharmD ; Vanthida Huang, PharmD ; Keith S. Kaye, MD, MPH ; Nicole Bonine, PhD, MPH ; Patrick Gillard, PharmD, MS ; Michael J. Rybak, PharmD, MPH, PhD
    Outcomes of Ceftaroline Fosamil q8h vs q12h Dosing Frequency for High-Burden, Gram-positive Infections
    Sonia Rao, PharmD ; Jennifer Hayes, PharmD ; Keith S. Kaye, MD, MPH ; Jie Chen, PhD ; Leonard Johnson, MD

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™

    ACPE Credits:

    ACPE Number:


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.